Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are both decreased in response to continuous EN administration, which may lead to increased insulin resistance, increased hepatic steatosis and may, in part, explain increased muscle catabolism in critically ill patients who receive continuous EN [42, 43]. The gene discussed is GIP; the disease is fatty liver disease.